KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Ratio (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 16 years of Equity Ratio data on record, last reported at 0.77 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 1.6% year-over-year to 0.77; the TTM value through Sep 2025 reached 0.77, down 1.6%, while the annual FY2024 figure was 0.78, 0.99% down from the prior year.
  • Equity Ratio reached 0.77 in Q3 2025 per REGN's latest filing, down from 0.78 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.79 in Q4 2023 and bottomed at 0.76 in Q2 2022.
  • Average Equity Ratio over 4 years is 0.78, with a median of 0.78 recorded in 2023.
  • Peak YoY movement for Equity Ratio: rose 3.03% in 2023, then decreased 1.6% in 2025.
  • A 4-year view of Equity Ratio shows it stood at 0.78 in 2022, then increased by 1.21% to 0.79 in 2023, then fell by 0.99% to 0.78 in 2024, then decreased by 0.86% to 0.77 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.77 in Q3 2025, 0.78 in Q2 2025, and 0.78 in Q1 2025.